TOT Biopharm International Co (HKSE:01875) Capex-to-Operating-Income : 3.09 (As of Jun. 2024)

TOT Biopharm International Co Capex-to-Operating-Income Chart

TOT Biopharm International Co Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Capex-to-Operating-Income	Get a 7-Day Free Trial									-	-	11.04	3.09	-

Competitive Comparison of TOT Biopharm International Co's Capex-to-Operating-Income

For the Biotechnology subindustry, TOT Biopharm International Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TOT Biopharm International Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TOT Biopharm International Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where TOT Biopharm International Co's Capex-to-Operating-Income falls into.

TOT Biopharm International Co Capex-to-Operating-Income Calculation

TOT Biopharm International Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

TOT Biopharm International Co's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TOT Biopharm International Co  (HKSE:01875) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

TOT Biopharm International Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of TOT Biopharm International Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

TOT Biopharm International Co Business Description